Non-Alcoholic Steatohepatitis and Metabolic Liver Disease
Madrigal Pharmaceuticals Inc. focuses on clinical research in NASH, with trials centered on disease activity, histological improvement, and prevention of progression in adults with fatty liver-related inflammation and fibrosis.
- Non-Alcoholic Steatohepatitis
- NAFLD activity score
- Fibrosis
- Liver biopsy
The sponsor’s studies examine liver tissue changes associated with NASH, including resolution of inflammatory features and improvement in scarring.
NASH Cirrhosis and Advanced Liver Disease
Its research also extends to NASH cirrhosis, addressing advanced chronic liver disease and clinical outcomes linked to hepatic decompensation and transplant risk.
- NASH cirrhosis
- Hepatic decompensation
- Liver transplant
- Model for End-stage Liver Disease (MELD) score
These trials focus on patients with well-compensated cirrhosis and track major liver-related outcomes relevant to advanced disease management.
Cardiometabolic and Liver-Related Outcomes
The sponsor’s trial portfolio includes outcomes research that links liver disease with broader cardiometabolic risk, including mortality and major clinical events.
- Liver-related mortality
- Cardiovascular mortality
- Composite clinical outcomes
- Hepatic encephalopathy
Clinical endpoints reflect interest in events that capture both hepatic progression and systemic consequences of advanced metabolic liver disease.
Oral Therapeutics for Liver Disease
Madrigal Pharmaceuticals Inc. is active in research on oral therapy for liver disease, with studies evaluating long-term safety and treatment response in patients receiving resmetirom and MGL-3196.
- Resmetirom
- MGL-3196
- Long-term safety
- Treatment response
Research activity includes follow-up beyond initial treatment periods to assess sustained effects in NASH and NASH cirrhosis.
